65,437 trials
Hematologic Malignancy · Hematopoietic/Lymphoid Cancer · Blood Cancer
Primary: Feasibility of Positive Psychology (PP) Intervention — 8.0 sessions completed out of 8 sessions
COVID-19 · Sars-CoV-2
Primary: Number of Participant Phone Surveys Conducted — 3 phone surveys
Endoscopy · Insufflation
Primary: Change in Abdominal Distension — 0.9; 0.5; 1.1; 0.9 cm
Breast Cancer
Primary: Number of Participants of Clinically Relevant Toxicities (CRT) — 36; 13; 42; 26 Participants
Dry Eye Syndrome
Primary: Central Corneal Staining Change From Baseline — -0.28; -0.3; -0.2 score on a scale
Metastatic Breast Cancer · Solid Tumors
Primary: The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by…
Palatal Wound
Primary: Size of Wound Area — 80; 80 micrometers (μm)
Urinary Retention · Urinary Incontinence
Primary: Number of Participants With Study-related Adverse Events at 6 Months — 2; 1; 1; 1 participants
Rheumatoid Arthritis
Primary: Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS — 78.8; 70.2; 199.5; 232.5 h*ng/mL
Open Angle Glaucoma · Ocular Hypertension
Primary: Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry — 15.39; 15.56; 15.64; 15.25 mmHg — p=<0.05
Parkinson's Disease
Primary: Adverse Events — 36 Number of Adverse Events
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Subjects With Any Adverse Event, Unexpected Adverse Event, Unexpected Serious Adverse Event, Adverse Event Leading to Discontinuation — 19.90; 13.65; 3.48…
Visual Acuity
Primary: Subjective Vision Scores — 61.41; 55.03 Units on a Scale
Bacterial Infection · Multiple-drug Resistance · Pathogen Resistance
Primary: Area Under the Concentration-time Curve (AUC 0-8 and AUC 0-inf ) of ZTI-01 — 780.9; 959.4; 1086.0 h*ug/mL
COVID-19 · Sars-CoV2
Primary: Number of Samples Tested — 3692 samples